FDA Brief

Warning letters Devices

FDA warning letter to

RoyalVibe Health Ltd.

High riskIssued Nov 18, 2022Posted Dec 27, 2022Center for Devices and Radiological Health

RoyalVibe Health marketed unapproved medical devices for cancer and other diseases and refused an FDA inspection.

What happened

FDA attempted an inspection at RoyalVibe Health in The Woodlands, TX from June 17, 2022 through July 5, 2022, but the firm did not permit the inspection and did not respond to later requests. FDA also reviewed the firm's websites and found claims that its products diagnose and treat diseases including cancer, Alzheimer's, stroke, arthritis, and type 1 diabetes. FDA determined the products lacked premarket approval or an investigational device exemption and that the firm had not submitted required 510(k) notification or FY2022 registration and listing.

What FDA found

  1. FDA says the products are adulterated because the firm lacks an approved premarket approval application or an approved investigational device exemption for devices intended to diagnose or treat disease.

    Section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  2. FDA says the devices are misbranded because the firm did not notify FDA of its intent to introduce them into commercial distribution as required for 510(k).

    Section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)
  3. FDA says the firm did not complete annual establishment registration and device listing for fiscal year 2022.

    Section 502(o), 21 U.S.C. § 352(o); section 510, 21 U.S.C. § 360
  4. FDA says the firm denied or limited an inspection of the establishment where its devices are processed, packed, or held.

    Section 501(j), 21 U.S.C. § 351(j)

What FDA wants

Within 15 business days, notify FDA in writing of specific steps taken and planned to correct the violations, prevent recurrence, and provide a timetable if actions will take longer. FDA also asks for a plan to address previously distributed adulterated devices and details on steps taken to remove the products from the US market.

Who should pay attention

  • device makers that use disease-treatment claims in consumer marketing
  • quality and regulatory teams preparing for FDA inspections
  • distributors or retailers selling wellness devices in the US

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  3. Ostar Beauty Sci-Tech Co Ltd.

    FDA warned Ostar Beauty Sci-Tech, a Chinese maker of microneedling pens, LED masks and fat-freezing pads, for selling unapproved medical devices in the US.

    High risk
  4. Med Pen Concepts, LLC

    FDA warned Med Pen Concepts about unapproved plasma skin devices and quality-system failures.

    High risk